

_ _

Net Sales/EBITDA by Segment



Rapid Antigen Test (ESPLINE SARS-CoV-2)


- Steady sales in Japan, emerging sales opportunity outside Japan Sf
- Superiority of 9D 9 •



Summary of New Medium-tere503rl



_ _



Key Takeaways

- ___ ___ / + + + ___

27